Nature of Business (Details)	12 Months Ended
	Dec. 31, 2016 USD ($) Patient ClinicalSite Country	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Nature of Business [Abstract]
Number of years Orphan Drug Designation provides several benefits of market exclusivity after approval	7 years
Number of years soft tissue sarcomas confers market among other benefits	10 years
Number of patients enrolled | Patient	433
Number of clinical sites | ClinicalSite	79
Number of countries | Country	15
Number of patients found to be statistically significant improvement in progression-free survival | Patient	246
Hazard ratio	0.62
Percentage of reduction in the risk of tumor progression	38.00%
Percentage of patients accounted to enrolled in the trial	57.00%
Number of patients treated | Patient	312
Percentage of total trial population	72.00%
Estimated Projected Expenditure Type [Line Items]
Number of years projected cash burn required to maintain	3 years
Projected cash burn	$ 10,000,000
Cash and cash equivalents	56,959,485	$ 22,261,372	$ 32,218,905	$ 11,483,112
Projected expenditures for clinical programs	39,800,000
Aldoxorubicin [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	16,400,000
Albumin-Binding Cancer Drugs [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	3,700,000
General Operation [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	3,200,000
Other General and Administrative Expenses [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	8,000,000
Interest and Principal Payments [Member]
Estimated Projected Expenditure Type [Line Items]
Projected expenditures for clinical programs	$ 8,500,000